A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs NXN 188 (Primary)
- Indications Migraine with aura
- Focus Therapeutic Use
- 26 Jun 2011 Results presented at the 15th Congress of the International Headache Society.
- 28 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Apr 2009 Planned end date ( Dec 2010) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History